Hear About Results of LUMINA Study on Racial Disparities in Lupus Thursday, May 17

Results of a study on arthritis treatment for lupus nephritis to be presented at medical meeting

Promising Early Results on Novel Lupus Treatment
New data from early studies of a novel compound IMO-8400 showed possible use as a treatment of systemic lupus erythematosus (SLE) and psoriasis. IMO-8400 is an inhibitor of specific Toll-like receptors (TLRs). The data were presented at the American Association of Immunologists (AAI) meeting being held in Boston, Massachusetts May 4-8, 2012. IMO-8400 is being developed by Idera Pharmaceuticals.

New Published Guidelines to Help Physicians Diagnose and Treat Lupus Kidney Disease

Drugs for Lupus and Other Diseases Could Come from the Sea

Published Research Shows Positive Findings in Treating Advanced Kidney Disease Caused by Lupus

Patient Tells Story of Successful Clinical Trial Participation

Interim Data for Investigational Lupus Treatment Showing Potential Promise

Obesity and Lack of Exercise May Diminish Intellectual Function in Lupus Patients, According to Study Findings

Prescription for Help if You Need it

FDA Working to Alleviate Shortage in Lupus treatment, Methotrexate

Lupus Research Institute Awards $3.6 Million for Novel Studies Driving Wide-Ranging New Science in Lupus

Information on Clinical trials Available on New National Institutes of Health Website
People can learn about participating in a clinical trial and lupus trials enrolling volunteers at clinicalresearchtrials.nih.gov.

New test launched to facilitate more accurate lupus diagnosis
A new test using innovative technology was launched today by Exagen to help physicians make a faster and more accurate diagnosis of lupus. The new test showed a high level of accuracy.

New Trial for Potential Lupus of the Skin Treatment
Rigel Pharmaceuticals, Inc. began a new Phase 1 clinical trial looking at a potential treatment for discoid lupus (lupus of the skin). Applied to the skin, R333 may be useful in treating acute and chronic phases of this potentially disfiguring disorder. R333 is a JAK/SYK inhibitor, which means it may inhibit Januse Kinase (JAK) and Spleen Tyrosine Kinase (Syk), both of which play a part in regulating inflammation. For more information, check Rigel Pharmaceutical's website.

New Trial Testing Benlysta as Injectable
The Lupus Research Institute is pleased to alert people with lupus of a new Phase III trial testing the efficacy, safety and tolerability of the recently approved Benlysta(r) as a once-a-week injectable rather than the existing intravenous formulation. For more information, visit clinicaltrials.gov and search for trial NCT01484496.